- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Diabetic Macular Oedema (DMO)
- Meeting Date: May 2022
- Public Summary Document (PSD) May 2022 PBAC Meeting - (PDF 915KB)
- Public Summary Document (PSD) May 2022 PBAC Meeting - (Word 613KB)
Faricimab – May 2022
Faricimab (diabetic macular oedema): Solution for intravitreal injection 28.8 mg in 0.24 mL; Vabysmo® – May 2022
Last updated
26 August 2022